5-(Morpholinomethyl)isoxazole-3-carbaldehyde | 893749-85-4

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 5-(Morpholinomethyl)isoxazole-3-carbaldehyde
• 英文别名: 5-(morpholin-4-ylmethyl)-1,2-oxazole-3-carbaldehyde
• CAS: 893749-85-4
• 化学式: C₉H₁₂N₂O₃
• mdl: MFCD06804219
• 分子量: 196.2
• InChiKey: AGLGFPIEVWZSLU-UHFFFAOYSA-N

物化性质

• 沸点：
  340.8±42.0 °C(Predicted)
• 密度：
  1.269±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  55.6
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• Compounds For Enzyme Inhibition
  申请人：Onyx Therapeutics, Inc.

  公开号：EP2623113A2

  公开（公告）日：2013-08-07

  Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.

  肽基化合物包括含杂原子的三元环，能有效并选择性地抑制与蛋白酶体相关的 N-末端亲核（Ntn）水解酶的特定活性。肽基化合物包括环氧化物或氮丙啶，并在 N 端进行了官能化。除其他治疗作用外，肽基化合物还具有抗炎和抑制细胞增殖的作用。由于这些肽基蛋白酶体抑制剂具有生物利用度高的特点，因此可以口服给药。
• ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS AND PHTHALOCYANINE CRYSTAL
  申请人：CANON KABUSHIKI KAISHA

  公开号：US20150301461A1

  公开（公告）日：2015-10-22

  The photosensitive layer of an electrophotographic photosensitive member contains a phthalocyanine crystal in which a compound represented by the following formula (1) is contained:
• MICROVESICLE AND STEM CELL COMPOSITIONS FOR THERAPEUTIC APPLICATIONS
  申请人：Ashraf Muhammad

  公开号：US20180273906A1

  公开（公告）日：2018-09-27

  Provided herein are stem cell and exosome compositions having therapeutic utility to treat a variety of diseases and disorders, e.g., cardiovascular disease, Duchenne muscular dystrophy, and fibrotic disease.
• CPC EXOSOMES MIRNA373 COMBINATION THERAPIES
  申请人：IPS Heart

  公开号：US20210054344A1

  公开（公告）日：2021-02-25

  Steam cell and exosome compositions via combination therapy, related gene therapy and pluripotent stem cell derived muscle regeneration as having therapeutic utility to treat a variety of diseases and disorders, e.g., cardiovascular disease, Duchenne muscular dystrophy, and fibrotic disease.